⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KTTA News
Pasithea Therapeutics Corp. Common Stock
Form 8-K
sec.gov
KTTAW
KTTA
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
globenewswire.com
KTTA
Form 8-K
sec.gov
KTTA
KTTAW
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
globenewswire.com
KTTA
Form 8-K
sec.gov
KTTAW
KTTA
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
globenewswire.com
KTTA
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
globenewswire.com
KTTA
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
globenewswire.com
KTTA
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
globenewswire.com
KTTA
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
globenewswire.com
KTTA